Benjamin Levy

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations

Medicine, Immunology, Oncology +17

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson et al. · New England Journal of Medicine · 2020 · 773 citations · Full text

Medicine, Endocrinology, Oncology +16

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

Karthik Suresh, Khinh Ranh Voong, Bairavi Shankar et al. · Journal of Thoracic Oncology · 2018 · 431 citations · Full text

Life Sciences, Immunology, Oncology +14

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Matthew S. Loftus, Maria Thadani‐Mulero, Benjamin Levy et al. · Cancer Research · 2011 · 427 citations · Full text

Medicine, Oncology, Pharmacology +17